US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
GB9514435D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Danisco |
Inhibition of gene expression
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
GB9519299D0
(en)
|
1995-09-21 |
1995-11-22 |
Farrar Gwyneth J |
Genetic strategy
|
GB9604449D0
(en)
*
|
1996-03-01 |
1996-05-01 |
Farrar Gwyneth J |
Genetic strategy ii
|
GB9606961D0
(en)
|
1996-04-02 |
1996-06-05 |
Farrar Gwyneth J |
Genetic strategy III
|
US8551970B2
(en)
|
1996-04-02 |
2013-10-08 |
Optigen Patents Limited |
Genetic suppression and replacement
|
US20030036519A1
(en)
*
|
1998-04-21 |
2003-02-20 |
Ryszard Kole |
Stable alteration of pre-mrna splicing patterns by modified rnas
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
AU2000240366B2
(en)
*
|
2000-03-28 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
EP1191097A1
(de)
*
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induktion von "exon-skipping" in eukaryotischen Zellen
|
GB2382577A
(en)
*
|
2001-11-28 |
2003-06-04 |
Talat Nasim |
A reporter-based assay for assessing relative RNA processing activity in mammaliian cells
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
ES2362878T3
(es)
|
2003-07-17 |
2011-07-14 |
Unilever N.V. |
Procedimiento para la preparación de una dispersión comestible que comprende aceite y agente estructurante.
|
WO2005072527A2
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
WO2005094370A2
(en)
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
US20090136645A1
(en)
|
2005-02-17 |
2009-05-28 |
Chiara Garbolino |
Granules Comprising Sterol
|
WO2006119137A1
(en)
*
|
2005-04-29 |
2006-11-09 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
|
LT3308788T
(lt)
|
2005-06-23 |
2018-12-10 |
Biogen Ma Inc. |
Kompozicijos ir būdai, skirti smn2 splaisingo moduliavimui
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
WO2007047913A2
(en)
|
2005-10-20 |
2007-04-26 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulation of lmna expression
|
JP2009515523A
(ja)
*
|
2005-11-10 |
2009-04-16 |
サンタリス ファーマ アー/エス |
Tnfスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
WO2008018795A1
(en)
|
2006-08-11 |
2008-02-14 |
Prosensa Technologies B.V. |
Methods and means for treating dna repeat instability associated genetic disorders
|
US20090264353A1
(en)
*
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
EP2173373B1
(de)
*
|
2007-06-06 |
2020-04-15 |
Sarepta Therapeutics, Inc. |
Lösliche her2- und her3-spleissvariantenproteine, spleissschaltende oligonukleotide und deren verwendung bei der behandlung von krankheiten
|
EP2167135A2
(de)
*
|
2007-07-12 |
2010-03-31 |
Prosensa Technologies B.V. |
Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe, gewebe oder tumorzellen
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
WO2009054725A2
(en)
|
2007-10-26 |
2009-04-30 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
US8637478B2
(en)
*
|
2007-11-13 |
2014-01-28 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2119783A1
(de)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
|
LT3133160T
(lt)
|
2008-10-24 |
2019-04-10 |
Sarepta Therapeutics, Inc. |
Kompozicijos su egzono praleidimu dmd gydymui
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
EP2393825A2
(de)
|
2009-02-06 |
2011-12-14 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
AU2010239779A1
(en)
|
2009-04-24 |
2011-11-17 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating DMD
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
CN103223177B
(zh)
*
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
CN102665731A
(zh)
|
2009-06-17 |
2012-09-12 |
Isis制药公司 |
用于在对象中调节smn2剪接的组合物和方法
|
EP2446036B1
(de)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
JP2013500017A
(ja)
|
2009-07-24 |
2013-01-07 |
カッパーアールエヌエー,インコーポレイテッド |
サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
US9044493B2
(en)
|
2009-08-11 |
2015-06-02 |
Curna, Inc. |
Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
EP2480669B1
(de)
|
2009-09-25 |
2017-11-08 |
CuRNA, Inc. |
Behandlung filaggrin (flg)-assoziierter erkrankungen durch modulierung der flg-expression und -aktivität
|
EE05711B1
(et)
*
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
CA2780563A1
(en)
|
2009-11-12 |
2011-05-19 |
The University Of Western Australia |
Antisense molecules and methods for treating pathologies
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
EP2516647B1
(de)
|
2009-12-24 |
2016-12-14 |
BioMarin Technologies B.V. |
Molekül zur Behandlung einer entzündlichen Erkrankung
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
JP5917497B2
(ja)
|
2010-05-26 |
2016-05-18 |
カッパーアールエヌエー,インコーポレイテッド |
メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療
|
RU2585229C2
(ru)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
|
MX2012014628A
(es)
|
2010-06-22 |
2013-02-07 |
Unilever Nv |
Polvos de grasa comestibles.
|
DK2585596T3
(da)
|
2010-06-23 |
2021-04-06 |
Curna Inc |
Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
CA2820354C
(en)
|
2010-12-17 |
2019-06-11 |
Unilever Plc |
Process of compacting a microporous fat powder and compacted fat powder so obtained
|
WO2012079957A1
(en)
|
2010-12-17 |
2012-06-21 |
Unilever Nv |
Edible water in oil emulsion
|
CN103687621A
(zh)
|
2011-06-08 |
2014-03-26 |
印第安纳大学研究与技术公司 |
用于诊断和治疗肺疾病和损伤的单克隆抗体和抗原
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
CN103874486A
(zh)
|
2011-09-06 |
2014-06-18 |
库尔纳公司 |
用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
EP2802674B1
(de)
|
2012-01-11 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation der ikbkap-aufspaltung
|
EP2806900B1
(de)
|
2012-01-27 |
2021-12-15 |
BioMarin Technologies B.V. |
Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
WO2013173608A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
SI2852668T1
(sl)
|
2012-07-12 |
2016-09-30 |
Proqr Therapeutics Ii B.V. |
Oligonukleotidi za izvedbo spremembe v sekvenci tarčne molekule rna, prisotne v živeči celici
|
EP2935584A1
(de)
|
2012-12-20 |
2015-10-28 |
Sarepta Therapeutics, Inc. |
Verbesserte exon-skipping-zusammensetzungen zur behandlung von muskeldystrophie
|
WO2014110291A1
(en)
|
2013-01-09 |
2014-07-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
SI2970964T1
(sl)
|
2013-03-14 |
2019-05-31 |
Sarepta Therapeutics, Inc. |
Sestavki, ki preskakujejo ekson za zdravljenje mišične distrofije
|
EA035882B1
(ru)
|
2013-03-14 |
2020-08-27 |
Сарепта Терапьютикс, Инк. |
Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
|
CN105307723A
(zh)
|
2013-03-15 |
2016-02-03 |
萨勒普塔医疗公司 |
改进的用于治疗肌营养不良的组合物
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
US10174328B2
(en)
|
2013-10-04 |
2019-01-08 |
Translate Bio Ma, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
EP4162940A1
(de)
|
2014-04-17 |
2023-04-12 |
Biogen MA Inc. |
Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung in einem patienten
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
WO2016054615A2
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
EP3271460A4
(de)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
Rna-interaktom des polycomb-repressiven komplexes 1 (prc1)
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
US11136584B2
(en)
|
2015-11-04 |
2021-10-05 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
SI3386511T1
(sl)
|
2015-12-10 |
2021-09-30 |
Ptc Therapeutics, Inc. |
Postopki za zdravljenje Huntingtonove bolezni
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
CN107338250B
(zh)
*
|
2016-05-03 |
2021-01-26 |
台中荣民总医院 |
对突变型多巴脱羧酶基因做剪接调整的反义寡核苷酸及其使用方法
|
US11198867B2
(en)
|
2016-06-16 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Combinations for the modulation of SMN expression
|
TW201811807A
(zh)
|
2016-06-30 |
2018-04-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
US11382981B2
(en)
|
2016-12-19 |
2022-07-12 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
AU2017382773A1
(en)
|
2016-12-19 |
2019-08-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
RS63610B1
(sr)
|
2016-12-19 |
2022-10-31 |
Sarepta Therapeutics Inc |
Oligomerni konjugati za preskakanje egzona za mišićnu distrofiju
|
KR102520654B1
(ko)
*
|
2017-03-10 |
2023-04-10 |
고쿠리츠켄큐카이하츠호진 고쿠리츠 세이쿠이료켄큐센타 |
안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물
|
EA201992878A1
(ru)
|
2017-06-05 |
2020-05-08 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения болезни хантингтона
|
US11395822B2
(en)
|
2017-06-28 |
2022-07-26 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's disease
|
BR112019027717A2
(pt)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics, Inc. |
métodos para tratar a doença de huntington
|
WO2019040923A1
(en)
|
2017-08-25 |
2019-02-28 |
Stoke Therapeutics, Inc. |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASE CONDITIONS AND OTHER DISEASES
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
CN115976028A
(zh)
*
|
2018-03-09 |
2023-04-18 |
第一三共株式会社 |
糖原病Ia型治疗药
|
WO2019190927A2
(en)
|
2018-03-26 |
2019-10-03 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
CA3094703A1
(en)
|
2018-03-27 |
2019-10-03 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
WO2020005873A1
(en)
|
2018-06-27 |
2020-01-02 |
Ptc Therapeutics, Inc. |
Heterocyclic and heteroaryl compounds for treating huntington's disease
|
EP3942049A4
(de)
|
2019-03-20 |
2023-10-18 |
President And Fellows Of Harvard College |
Antisense-oligonukleotid basierte progranulin-augmentationstherapie bei neurodegenerativen erkrankungen
|
JP2022528725A
(ja)
|
2019-04-18 |
2022-06-15 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを治療するための組成物
|
CN112111528B
(zh)
*
|
2019-06-21 |
2024-04-02 |
华东师范大学 |
一种内含子异常剪接的修复方法
|
WO2021084495A1
(en)
|
2019-11-01 |
2021-05-06 |
Novartis Ag |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|
TW202134438A
(zh)
*
|
2019-12-02 |
2021-09-16 |
日商第一三共股份有限公司 |
著色性乾皮症f群組治療藥
|
US20220064638A1
(en)
|
2020-02-28 |
2022-03-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
TW202208627A
(zh)
|
2020-05-11 |
2022-03-01 |
美商斯托克治療公司 |
用於病症及疾病之治療的opa1反義寡聚物
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|